GDF15 blockade can reduce immunotherapy resistance in urothelial cancer

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2025-02-11 DOI:10.1038/s41585-025-01005-x

Maria Chiara Masone

引用次数: 0

查看原文本刊更多论文

阻断GDF15可降低尿路上皮癌的免疫治疗耐药

发表在《自然》杂志上的一项新研究报告了GDFATHER的I/IIa期研究结果，显示中和性抗gdf15抗体visugromab与抗pd1抗体nivolumab联合治疗尿路上皮癌患者的协同效应。该试验建立在临床前模型的基础上，结果显示GDF15阻断剂增强了pd1介导的免疫治疗的疗效，表明抗GDF15抗体在减轻免疫治疗耐药性方面的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.